Clinical Fellowships for Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
This grant funds clinical fellowships at U.S. academic institutions to train physicians in the diagnosis, management, and research of Transthyretin-mediated (ATTR) Amyloidosis.
Funder: Alnylam Pharmaceuticals
Due Dates: August 28, 2026
Funding Amounts: Up to $95,000 per institution for a one-year clinical fellowship; funds are for salary and fellow benefits only.
Summary: Supports U.S. academic institutions in training physicians in the diagnosis, treatment, and research of Transthyretin-mediated (ATTR) Amyloidosis.
Key Information: Grants are awarded to institutions (not individuals); only ACGME-accredited programs with active Cardiology Fellowships are eligible.
Description
This grant provides support for U.S. academic healthcare organizations to develop or enhance clinical fellowship programs focused on Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). The goal is to advance physician training in the diagnosis, management, and research of ATTR Amyloidosis, foster multidisciplinary collaboration, and accelerate the translation of emerging scientific knowledge into patient-centered care. Funding is intended for fellow salary and benefits only, and the program must include comprehensive, multidisciplinary training and research opportunities.
